TABLE 3.
Hazard ratios (HR) and 95 % confidence intervals (CI) for the effects of listed variables on recurrence-free survival
| Variable | Univariate analysis
|
Multivariate analysis
|
||
|---|---|---|---|---|
| HR (95 % CI) | P | HR (95 % CI) | P | |
| Group | ||||
| No CALND vs. CALND | 1.40 (0.65–2.99) | 0.387 | 1.20 (0.55–2.62) | 0.643 |
| Age | ||||
| Per 1-year increase | 0.97 (0.94–1.00) | 0.089 | ||
| Race | ||||
| Black vs. White | 1.23 (0.52–2.89) | 0.639 | ||
| Other vs. White | 2.47 (0.58–10.6) | 0.221 | ||
| Tumor size | ||||
| T2–4 vs. T1 | 1.83 (0.89–3.74) | 0.098 | ||
| Tumor histology | ||||
| Lobular vs. ductal | 0.25 (0.03–1.86) | 0.177 | ||
| Others vs. ductal | 0.22 (0.03–1.63) | 0.139 | ||
| ER status | ||||
| Positive vs. negative | 0.19 (0.09–0.40) | <0.0001 | 0.20 (0.10–0.41) | <0.0001 |
| PR status | ||||
| Positive vs. negative | 0.26 (0.12–0.56) | 0.0005 | ||
| Her-2neu status | ||||
| Amplified vs. not | 1.34 (0.60–3.04) | 0.478 | ||
| Tumor grade | ||||
| Grade II vs. grade I | 7.85 (1.02–60.30) | 0.048 | ||
| Grade III vs. grade I | 19.70 (2.62–147.94) | 0.004 | ||
| Lymphovascular invasion | ||||
| Present vs. absent | 2.13 (1.02–4.42) | 0.043 | 2.11 (1.00–4.47) | 0.051 |
| Micrometastatic SLN | ||||
| Micro- vs. macrometastatic | 0.66 (0.27–1.60) | 0.353 | ||
| Surgical therapy | ||||
| Mastectomy vs. BCT | 1.49 (0.73–3.06) | 0.276 | ||
| Axillary radiation therapy | ||||
| Yes vs. no | 1.63 (0.59–4.47) | 0.347 | ||
CALND completion axillary lymph node dissection, ER estrogen receptor, PR progesterone receptor, SLN sentinel lymph node, BCT breast-conservation therapy